Aditya Birla Sun Life Nifty IT ETF logo

Aditya Birla Sun Life Nifty IT ETF (TECH)

Market Closed
4 Jul, 10:00
XNSE XNSE
41. 48
+0.29
+0.7%
- Market Cap
0.32% Div Yield
7,733 Volume
41.19
Previous Close
Day Range
40.96 41.97
Year Range
33.41 49.77
Want to track TECH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 38 days

Summary

TECH closed yesterday higher at ₹41.48, an increase of 0.7% from Thursday's close, completing a monthly increase of 3.06% or ₹1.23. Over the past 12 months, TECH stock lost -8.96%.
TECH pays dividends to its shareholders, with the most recent payment made on May 30, 2025. The next estimated payment will be in In 1 month on Aug 30, 2025 for a total of ₹0.08.
The last earnings report, released on Apr 29, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports. The next scheduled earnings report is due on Aug 12, 2025.
Aditya Birla Sun Life Nifty IT ETF has completed 1 stock splits, with the recent split occurring on Nov 30, 2022.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

TECH Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock

TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.

Zacks | 4 days ago
Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

MINNEAPOLIS , June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160 antibody therapies against nearly 100 targets and range of diseases have been approved worldwide.

Prnewswire | 1 week ago
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.

Prnewswire | 3 weeks ago

Aditya Birla Sun Life Nifty IT ETF Dividends

Bio-Techne Corporation logo
TECH In 1 month
Estimated
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 1 month ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 4 months ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 7 months ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 10 months ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 10 May 2024
Paid
Quarterly
$0.08 Per Share

Aditya Birla Sun Life Nifty IT ETF Earnings

12 Aug 2025 (In 1 month) Date
0.5
Cons. EPS
-
EPS
29 Apr 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
0.39
Cons. EPS
0.42
EPS
30 Oct 2024 Date
0.38
Cons. EPS
0.42
EPS
29 Oct 2024 Date
-
Cons. EPS
-
EPS
Bio-Techne Corporation logo
TECH In 1 month
Estimated
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 1 month ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 4 months ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 7 months ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 10 months ago
Paid
Quarterly
$0.08 Per Share
Bio-Techne Corporation logo
TECH 10 May 2024
Paid
Quarterly
$0.08 Per Share
12 Aug 2025 (In 1 month) Date
0.5
Cons. EPS
-
EPS
29 Apr 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
0.39
Cons. EPS
0.42
EPS
30 Oct 2024 Date
0.38
Cons. EPS
0.42
EPS
29 Oct 2024 Date
-
Cons. EPS
-
EPS

Aditya Birla Sun Life Nifty IT ETF (TECH) FAQ

What is the stock price today?

The current price is ₹41.48.

On which exchange is it traded?

Aditya Birla Sun Life Nifty IT ETF is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is TECH.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.32%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.5.

When is the next earnings date?

The next earnings report will release on Aug 12, 2025.

Has Aditya Birla Sun Life Nifty IT ETF ever had a stock split?

Aditya Birla Sun Life Nifty IT ETF had 1 splits and the recent split was on Nov 30, 2022.

Aditya Birla Sun Life Nifty IT ETF Profile

XNSE Exchange
US Country

Overview

Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.

Products and Services

Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments:

  • Protein Sciences: The cornerstone of Bio-Techne's offerings, this segment focuses on the development and manufacturing of biological reagents critical for life science research, diagnostics, and cell and gene therapy advancements. Products include:
    • Cytokines and growth factors: Essential for studying cell signaling and communication.
    • Antibodies: Integral for detecting and quantifying target proteins.
    • Small molecules: Used in various experimental applications to modulate biological processes.
    • Tissue culture sera: Provides a nutritious environment for cell culture growth.
    • Cell selection technologies: Enables the isolation of specific cell types for research or therapeutic use.
    • Proteomic analytical tools: Includes instruments and immunoassays for protein analysis in biological fluids, facilitating automated western blot and multiplexed ELISA workflows.
  • Diagnostics and Genomics: This segment is geared towards the development and manufacture of products for the regulated diagnostics market as well as for research and clinical applications involving genomics and oncology. Offerings include:
    • Diagnostic products: Comprising controls, calibrators, and assays for quality assurance in diagnostic testing.
    • Exosome-based molecular diagnostic assays: Innovative solutions for detecting disease markers at a molecular level.
    • Tissue-based in-situ hybridization assays: Advanced tools for spatial genomic analysis and biopsy examination.
    • Genetic and oncology kits: Facilitate research and clinical applications in genetics and cancer diagnostics.
    • Carrier screening and oncology diagnostics: Support genetic testing and cancer detection and monitoring.
    • Molecular controls: Provide benchmarks for ensuring accuracy in molecular diagnostic tests.
    • Process control products: Essential for maintaining quality in hematology, blood chemistry, and coagulation diagnostics.

Contact Information

Address: 614 McKinley Place N.E.
Phone: 612 379 8854